Pretreatment with angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion injury
Background. The Heart Outcomes Prevention Evaluation (HOPE) trial demonstrated that ischemic events are decreased in patients receiving angiotensin-converting enzyme (ACE) inhibitors. This study sought to determine whether pretreatment with ACE inhibitors would attentuate ischemic injury during surg...
Gespeichert in:
| Veröffentlicht in: | The Annals of thoracic surgery 2002-05, Vol.73 (5), p.1522-1527 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1527 |
|---|---|
| container_issue | 5 |
| container_start_page | 1522 |
| container_title | The Annals of thoracic surgery |
| container_volume | 73 |
| creator | Lazar, Harold L Bao, Yusheng Rivers, Samuel Bernard, Sheilah A |
| description | Background. The Heart Outcomes Prevention Evaluation (HOPE) trial demonstrated that ischemic events are decreased in patients receiving angiotensin-converting enzyme (ACE) inhibitors. This study sought to determine whether pretreatment with ACE inhibitors would attentuate ischemic injury during surgical revascularization of ischemic myocardium.
Methods. In a porcine model, the second and third diagonal vessels were occluded for 90 minutes, followed by 45 minutes of cardioplegic arrest, and 180 minutes of reperfusion. Ten pigs received quinapril (20 mg PO q.d.) for 7 days prior to surgery; 10 others received no-ACE inhibitors.
Results. Quinapril-treated animals required less cardioversions for ventricular arrhythmias (1.58 ± 0.40 vs 2.77 ± 0.22;
p < 0.05), had higher wall motion scores assessed by two-dimensional echocardiography (4 = normal to −1 = dyskinesia; 2.11 ± 0.10 vs 1.50 ± 0.07;
p < 0.05), more complete coronary artery endothelial relaxation to bradykinin (45% ± 3% vs 7% ± 4%;
p < 0.005), and lower infarct size (24.0% ± 3.0% vs 40.0% ± 1.7%;
p < 0.0001).
Conclusions. ACE inhibition prior to coronary revascularization enhances myocardial protection by decreasing ventricular irritability, improving regional wall motion, lowering infarct size, and preserving endothelial function. |
| doi_str_mv | 10.1016/S0003-4975(02)03461-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71703620</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0003497502034616</els_id><sourcerecordid>71703620</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-a45fc44073d29761122424205ed78219b572e876fd749c542bb6fa9c49f886913</originalsourceid><addsrcrecordid>eNqFkEtLJDEQgIO46Kj7E5S-uOihNUnn0TnJIusDBhR0zyGdrnYi0-kxSc8y--vNOIMepQ5FUV89-BA6JviCYCIunzDGVcmU5GeYnuOKCVKKHTQhnNNSUK520eQT2UcHMb7mkub2HtonFFPKWTVB5jFACmBSDz4V_1yaFca_uCGBj86XdvBLCMn5lwL8_1UPhfMz17g0hFiYlKnRJIiFi3YGvTNlgAWEboxu8Bl9HcPqCP3ozDzCz20-RH9v_jxf35XTh9v769_T0jLJUmkY7yxjWFYtVVIQQinLgTm0sqZENVxSqKXoWsmU5Yw2jeiMskx1dS0UqQ7Rr83eRRjeRohJ9_krmM-Nh2GMWhKJK0FxBvkGtGGIMUCnF8H1Jqw0wXrtVn-41WtxGlP94VaLPHeyPTA2PbRfU1uZGTjdAiZaM--C8dbFL64SXNG6ztzVhoOsY-kg6GgdeAutC2CTbgf3zSvvofqXOQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71703620</pqid></control><display><type>article</type><title>Pretreatment with angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion injury</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Lazar, Harold L ; Bao, Yusheng ; Rivers, Samuel ; Bernard, Sheilah A</creator><creatorcontrib>Lazar, Harold L ; Bao, Yusheng ; Rivers, Samuel ; Bernard, Sheilah A</creatorcontrib><description>Background. The Heart Outcomes Prevention Evaluation (HOPE) trial demonstrated that ischemic events are decreased in patients receiving angiotensin-converting enzyme (ACE) inhibitors. This study sought to determine whether pretreatment with ACE inhibitors would attentuate ischemic injury during surgical revascularization of ischemic myocardium.
Methods. In a porcine model, the second and third diagonal vessels were occluded for 90 minutes, followed by 45 minutes of cardioplegic arrest, and 180 minutes of reperfusion. Ten pigs received quinapril (20 mg PO q.d.) for 7 days prior to surgery; 10 others received no-ACE inhibitors.
Results. Quinapril-treated animals required less cardioversions for ventricular arrhythmias (1.58 ± 0.40 vs 2.77 ± 0.22;
p < 0.05), had higher wall motion scores assessed by two-dimensional echocardiography (4 = normal to −1 = dyskinesia; 2.11 ± 0.10 vs 1.50 ± 0.07;
p < 0.05), more complete coronary artery endothelial relaxation to bradykinin (45% ± 3% vs 7% ± 4%;
p < 0.005), and lower infarct size (24.0% ± 3.0% vs 40.0% ± 1.7%;
p < 0.0001).
Conclusions. ACE inhibition prior to coronary revascularization enhances myocardial protection by decreasing ventricular irritability, improving regional wall motion, lowering infarct size, and preserving endothelial function.</description><identifier>ISSN: 0003-4975</identifier><identifier>EISSN: 1552-6259</identifier><identifier>DOI: 10.1016/S0003-4975(02)03461-6</identifier><identifier>PMID: 12022543</identifier><identifier>CODEN: ATHSAK</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Anesthesia ; Anesthesia depending on type of surgery ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Angiotensin-Converting Enzyme Inhibitors - pharmacology ; Animals ; Biological and medical sciences ; Coronary Circulation - drug effects ; Coronary Circulation - physiology ; Electrocardiography - drug effects ; Hemodynamics - drug effects ; Hemodynamics - physiology ; Isoquinolines - pharmacology ; Medical sciences ; Myocardial Reperfusion Injury - physiopathology ; Myocardial Reperfusion Injury - prevention & control ; Premedication ; Quinapril ; Swine ; Tetrahydroisoquinolines ; Thoracic and cardiovascular surgery. Cardiopulmonary bypass ; Treatment Outcome ; Ventricular Fibrillation - physiopathology ; Ventricular Fibrillation - prevention & control</subject><ispartof>The Annals of thoracic surgery, 2002-05, Vol.73 (5), p.1522-1527</ispartof><rights>2002 The Society of Thoracic Surgeons</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-a45fc44073d29761122424205ed78219b572e876fd749c542bb6fa9c49f886913</citedby><cites>FETCH-LOGICAL-c474t-a45fc44073d29761122424205ed78219b572e876fd749c542bb6fa9c49f886913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0003497502034616$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13659288$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12022543$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lazar, Harold L</creatorcontrib><creatorcontrib>Bao, Yusheng</creatorcontrib><creatorcontrib>Rivers, Samuel</creatorcontrib><creatorcontrib>Bernard, Sheilah A</creatorcontrib><title>Pretreatment with angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion injury</title><title>The Annals of thoracic surgery</title><addtitle>Ann Thorac Surg</addtitle><description>Background. The Heart Outcomes Prevention Evaluation (HOPE) trial demonstrated that ischemic events are decreased in patients receiving angiotensin-converting enzyme (ACE) inhibitors. This study sought to determine whether pretreatment with ACE inhibitors would attentuate ischemic injury during surgical revascularization of ischemic myocardium.
Methods. In a porcine model, the second and third diagonal vessels were occluded for 90 minutes, followed by 45 minutes of cardioplegic arrest, and 180 minutes of reperfusion. Ten pigs received quinapril (20 mg PO q.d.) for 7 days prior to surgery; 10 others received no-ACE inhibitors.
Results. Quinapril-treated animals required less cardioversions for ventricular arrhythmias (1.58 ± 0.40 vs 2.77 ± 0.22;
p < 0.05), had higher wall motion scores assessed by two-dimensional echocardiography (4 = normal to −1 = dyskinesia; 2.11 ± 0.10 vs 1.50 ± 0.07;
p < 0.05), more complete coronary artery endothelial relaxation to bradykinin (45% ± 3% vs 7% ± 4%;
p < 0.005), and lower infarct size (24.0% ± 3.0% vs 40.0% ± 1.7%;
p < 0.0001).
Conclusions. ACE inhibition prior to coronary revascularization enhances myocardial protection by decreasing ventricular irritability, improving regional wall motion, lowering infarct size, and preserving endothelial function.</description><subject>Anesthesia</subject><subject>Anesthesia depending on type of surgery</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Angiotensin-Converting Enzyme Inhibitors - pharmacology</subject><subject>Animals</subject><subject>Biological and medical sciences</subject><subject>Coronary Circulation - drug effects</subject><subject>Coronary Circulation - physiology</subject><subject>Electrocardiography - drug effects</subject><subject>Hemodynamics - drug effects</subject><subject>Hemodynamics - physiology</subject><subject>Isoquinolines - pharmacology</subject><subject>Medical sciences</subject><subject>Myocardial Reperfusion Injury - physiopathology</subject><subject>Myocardial Reperfusion Injury - prevention & control</subject><subject>Premedication</subject><subject>Quinapril</subject><subject>Swine</subject><subject>Tetrahydroisoquinolines</subject><subject>Thoracic and cardiovascular surgery. Cardiopulmonary bypass</subject><subject>Treatment Outcome</subject><subject>Ventricular Fibrillation - physiopathology</subject><subject>Ventricular Fibrillation - prevention & control</subject><issn>0003-4975</issn><issn>1552-6259</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtLJDEQgIO46Kj7E5S-uOihNUnn0TnJIusDBhR0zyGdrnYi0-kxSc8y--vNOIMepQ5FUV89-BA6JviCYCIunzDGVcmU5GeYnuOKCVKKHTQhnNNSUK520eQT2UcHMb7mkub2HtonFFPKWTVB5jFACmBSDz4V_1yaFca_uCGBj86XdvBLCMn5lwL8_1UPhfMz17g0hFiYlKnRJIiFi3YGvTNlgAWEboxu8Bl9HcPqCP3ozDzCz20-RH9v_jxf35XTh9v769_T0jLJUmkY7yxjWFYtVVIQQinLgTm0sqZENVxSqKXoWsmU5Yw2jeiMskx1dS0UqQ7Rr83eRRjeRohJ9_krmM-Nh2GMWhKJK0FxBvkGtGGIMUCnF8H1Jqw0wXrtVn-41WtxGlP94VaLPHeyPTA2PbRfU1uZGTjdAiZaM--C8dbFL64SXNG6ztzVhoOsY-kg6GgdeAutC2CTbgf3zSvvofqXOQ</recordid><startdate>20020501</startdate><enddate>20020501</enddate><creator>Lazar, Harold L</creator><creator>Bao, Yusheng</creator><creator>Rivers, Samuel</creator><creator>Bernard, Sheilah A</creator><general>Elsevier Inc</general><general>Elsevier Science</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020501</creationdate><title>Pretreatment with angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion injury</title><author>Lazar, Harold L ; Bao, Yusheng ; Rivers, Samuel ; Bernard, Sheilah A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-a45fc44073d29761122424205ed78219b572e876fd749c542bb6fa9c49f886913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Anesthesia</topic><topic>Anesthesia depending on type of surgery</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Angiotensin-Converting Enzyme Inhibitors - pharmacology</topic><topic>Animals</topic><topic>Biological and medical sciences</topic><topic>Coronary Circulation - drug effects</topic><topic>Coronary Circulation - physiology</topic><topic>Electrocardiography - drug effects</topic><topic>Hemodynamics - drug effects</topic><topic>Hemodynamics - physiology</topic><topic>Isoquinolines - pharmacology</topic><topic>Medical sciences</topic><topic>Myocardial Reperfusion Injury - physiopathology</topic><topic>Myocardial Reperfusion Injury - prevention & control</topic><topic>Premedication</topic><topic>Quinapril</topic><topic>Swine</topic><topic>Tetrahydroisoquinolines</topic><topic>Thoracic and cardiovascular surgery. Cardiopulmonary bypass</topic><topic>Treatment Outcome</topic><topic>Ventricular Fibrillation - physiopathology</topic><topic>Ventricular Fibrillation - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lazar, Harold L</creatorcontrib><creatorcontrib>Bao, Yusheng</creatorcontrib><creatorcontrib>Rivers, Samuel</creatorcontrib><creatorcontrib>Bernard, Sheilah A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Annals of thoracic surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lazar, Harold L</au><au>Bao, Yusheng</au><au>Rivers, Samuel</au><au>Bernard, Sheilah A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pretreatment with angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion injury</atitle><jtitle>The Annals of thoracic surgery</jtitle><addtitle>Ann Thorac Surg</addtitle><date>2002-05-01</date><risdate>2002</risdate><volume>73</volume><issue>5</issue><spage>1522</spage><epage>1527</epage><pages>1522-1527</pages><issn>0003-4975</issn><eissn>1552-6259</eissn><coden>ATHSAK</coden><abstract>Background. The Heart Outcomes Prevention Evaluation (HOPE) trial demonstrated that ischemic events are decreased in patients receiving angiotensin-converting enzyme (ACE) inhibitors. This study sought to determine whether pretreatment with ACE inhibitors would attentuate ischemic injury during surgical revascularization of ischemic myocardium.
Methods. In a porcine model, the second and third diagonal vessels were occluded for 90 minutes, followed by 45 minutes of cardioplegic arrest, and 180 minutes of reperfusion. Ten pigs received quinapril (20 mg PO q.d.) for 7 days prior to surgery; 10 others received no-ACE inhibitors.
Results. Quinapril-treated animals required less cardioversions for ventricular arrhythmias (1.58 ± 0.40 vs 2.77 ± 0.22;
p < 0.05), had higher wall motion scores assessed by two-dimensional echocardiography (4 = normal to −1 = dyskinesia; 2.11 ± 0.10 vs 1.50 ± 0.07;
p < 0.05), more complete coronary artery endothelial relaxation to bradykinin (45% ± 3% vs 7% ± 4%;
p < 0.005), and lower infarct size (24.0% ± 3.0% vs 40.0% ± 1.7%;
p < 0.0001).
Conclusions. ACE inhibition prior to coronary revascularization enhances myocardial protection by decreasing ventricular irritability, improving regional wall motion, lowering infarct size, and preserving endothelial function.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>12022543</pmid><doi>10.1016/S0003-4975(02)03461-6</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4975 |
| ispartof | The Annals of thoracic surgery, 2002-05, Vol.73 (5), p.1522-1527 |
| issn | 0003-4975 1552-6259 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71703620 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Anesthesia Anesthesia depending on type of surgery Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Angiotensin-Converting Enzyme Inhibitors - pharmacology Animals Biological and medical sciences Coronary Circulation - drug effects Coronary Circulation - physiology Electrocardiography - drug effects Hemodynamics - drug effects Hemodynamics - physiology Isoquinolines - pharmacology Medical sciences Myocardial Reperfusion Injury - physiopathology Myocardial Reperfusion Injury - prevention & control Premedication Quinapril Swine Tetrahydroisoquinolines Thoracic and cardiovascular surgery. Cardiopulmonary bypass Treatment Outcome Ventricular Fibrillation - physiopathology Ventricular Fibrillation - prevention & control |
| title | Pretreatment with angiotensin-converting enzyme inhibitors attenuates ischemia-reperfusion injury |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T15%3A51%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pretreatment%20with%20angiotensin-converting%20enzyme%20inhibitors%20attenuates%20ischemia-reperfusion%20injury&rft.jtitle=The%20Annals%20of%20thoracic%20surgery&rft.au=Lazar,%20Harold%20L&rft.date=2002-05-01&rft.volume=73&rft.issue=5&rft.spage=1522&rft.epage=1527&rft.pages=1522-1527&rft.issn=0003-4975&rft.eissn=1552-6259&rft.coden=ATHSAK&rft_id=info:doi/10.1016/S0003-4975(02)03461-6&rft_dat=%3Cproquest_cross%3E71703620%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71703620&rft_id=info:pmid/12022543&rft_els_id=S0003497502034616&rfr_iscdi=true |